A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide

Journal of Women's Health

Volumn 12, Issue 3, 2003, Pages 255-259

  Harwell, Joseph I ^a   Moench, Thomas ^b   Mayer, Kenneth H ^a   Chapman, Stacey ^a   Rodriguez, Irma ^a   Cu Uvin, Susan ^a  

^a BROWN UNIVERSITY   (United States)

^b REPROTECT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BUFFER; CARBOPOL 974P; METRONIDAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAM STAINING; HUMAN; MEDICAL ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; SCREENING TEST; SIDE EFFECT; TREATMENT OUTCOME; VAGINITIS;

EID: 0038780783     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/154099903321667591     Document Type: Article

References (12)

1. Hillier S, Holmes KK. Bacterial vaginosis. In: Holme KK, Sparling PF, Mardh PA, et al., eds. Sexually transmitted diseases, 3rd ed. New York: McGraw-Hill, 1999;563.
2. Taha TE, Gray RH, Kumwenda NI, et al. HIV infection and disturbances of vaginal flora during pregnancy. J Acquir Immune Defic Syndr 1999;20:52.
3. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297.
4. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14.
5. Nagy E, Froman G, Mardh PA. Fibronectin binding of Lactobacillus species isolated from women with and without bacterial vaginosis. J Med Microbiol 1992;37:38.
6. Andersch B, Forssman L, Lincoln K, Torstensson P. Treatment of bacterial vaginosis with an acid cream: A comparison between the effect of lactate-gel and metronidazole. Gynecol Obstet Invest 19.
7. Livengood CH 3rd, Soper DE, Sheehan KL, et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis 1999;26:137.
8. Mayer KH, Peipert J, Fleming T, et al. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 2001; 32:476.
9. van De Wijgert J, Fullem A, Kelly C, et al. Phase I trial of the topical microbicide BufferGel: Safety results from four international sites. J Acquir Immune Defic Syndr 2001;26:21.
10. Smith D. The HIV epidemiolgy research study, HIV out-patient study, and spectrum of disease studies. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(Suppl 1):s17.
11. Cu-Uvin S, Hogan JW, Warren D, et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis 1999;29:1145.
12. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med 2000;342:534.